TrialLeukemia2013

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

F J Giles et al.PubMed ↗Publisher ↗

No numbers read from the abstract.